Plain-English fact sheet
GHRP-2
Also known as growth hormone-releasing peptide-2, pralmorelin
GHRP-2 can stimulate growth hormone and food intake in small human studies, but it is not FDA approved and does not have strong evidence for muscle gain, recovery, fat loss, or anti-aging.
Quick answer
GHRP-2 is an experimental growth-hormone secretagogue that activates the ghrelin receptor. It is not FDA approved, and small human physiology studies do not prove that it builds muscle, improves recovery, or slows aging.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is GHRP-2?
GHRP-2 is a synthetic six-amino-acid peptide that activates the growth-hormone secretagogue receptor, also called the ghrelin receptor.
It can increase growth-hormone release and appetite, but a hormone spike is a biomarker—not a demonstrated body-composition or performance outcome.
Why are people interested in it?
It is promoted online for muscle growth, recovery, fat loss, sleep, and anti-aging, sometimes alongside other growth-hormone-pathway peptides.
Human studies more clearly show appetite and hormone effects than the desired performance outcomes used in marketing.
Current regulatory status
GHRP-2 is not FDA approved. FDA places GHRP-2 for injectable and nasal routes in a compounding category associated with potential significant safety risks.
What is it approved for?
No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.
What is it being studied for?
Investigational areas
- Growth-hormone and ghrelin-receptor physiology
- Appetite and metabolic research
Evidence snapshot
Small controlled human studies establish short-term effects on growth hormone and food intake. They do not establish meaningful muscle growth, recovery, fat loss, sleep, or longevity benefits.
Potential benefits being researched
- Small controlled studies show increased growth hormone and short-term food intake.
- Those biological effects do not demonstrate improved muscle mass, strength, recovery, or healthspan.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- FDA identifies potential immune reactions, aggregation, peptide impurities, and complexity from an unnatural amino acid.
- FDA notes reports of increased insulin requirements, infection, pancreatitis, and deaths in critically ill study participants, while stating that causality was not established.
- The peptide can increase appetite and may affect glucose and endocrine signaling in ways that conflict with popular body-composition claims.
What we still do not know
- Long-term human safety
- Whether any meaningful muscle, strength, recovery, sleep, or body-composition benefit exists
- Risks of combinations with other growth-hormone-pathway substances
- Product identity and quality outside an approved drug application
Plain-English takeaway
GHRP-2 reliably illustrates a common research trap: showing that a peptide changes a hormone does not show that it builds useful muscle or improves performance safely.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA: safety risks for selected compounded bulk substances
FDA's current substance-specific summary of evidence gaps and potential safety risks.
- 2GHRP-2 food-intake study in healthy men
Small controlled physiology study of growth hormone and short-term food intake.
- 3Randomized GHRP-2 appetite study
Small double-blind study showing exposure-related food-intake and hormone effects, not muscle benefit.
- 4Randomized GHRP-2 endocrine physiology study
Controlled hormone-secretion study in young men; it did not test performance outcomes.